Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.65 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.65 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7933990 | 0.86 | MEN1 (0.60) | NTRK1ALDH1A1HTTL3MBTL1ATM | |
| SCHEMBL15717788 | 0.85 | NTRK1 (0.85) | NTRK1ALDH1A1HTTL3MBTL1ATM | |
| SCHEMBL16595134 | 0.84 | NTRK1 (1.00) | NTRK1ALDH1A1HTTL3MBTL1ATM | |
| SCHEMBL7933995 | 0.84 | NTRK1 (0.53) | NTRK1ALDH1A1HTTL3MBTL1ATM | |
| SCHEMBL25793172 | 0.82 | NTRK1 (0.80) | NTRK1ALDH1A1HTTL3MBTL1ATM | |
| SCHEMBL7934313 | 0.82 | MAPT (0.79) | NTRK1ALDH1A1HTTKMT2ALMNA | |
| SCHEMBL21783121 | 0.81 | ABCB1 (0.67) | ALDH1A1HTTGAAKMT2ALMNA | |
| SCHEMBL13975495 | 0.81 | NTRK1 (0.78) | NTRK1ALDH1A1HTTL3MBTL1ATM | |
| SCHEMBL4130247 | 0.81 | SOAT2 (0.75) | NTRK1ALDH1A1HTTL3MBTL1ATM | |
| SCHEMBL7932253 | 0.80 | LMNA (0.71) | NTRK1ALDH1A1HTTL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | NTRK1 4503/4885ALDH1A1 496/4885HTT 1082/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | NTRK1 1557/4885ALDH1A1 2213/4885HTT 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.